Photo of Rita M. Braziel, M.D.

Rita M. Braziel M.D.

    • Professor of Pathology School of Medicine
    • Medical Director, Hematopathology

The focus of Dr. Braziel's services include hematopathology, which comprise of bone marrow, lymph nodes, hemepath flow cytometry and hemepath molecular diagnostic cases. Her clinical areas of interest are all areas of diagnostic hematopathology and standardization of molecular diagnostic in hematopathology. Dr. Braziel currently serves as the director of hematopathology at OHSU.

Areas of interest

  • All areas of diagnostic hematopathology
  • Standardization of molecular diagnostic testing in hematopathology
  • Identification of biologic markers of diagnostic, prognostic and therapeutic importance in malignant lymphomas

Education

  • B.S., University of New Mexico 1972
  • M.D., University of New Mexico 1977
  • Residency:

    • Anatomic and Clinical Pathology, University of New Mexico Affiliated Hospitals, 1977-1981
  • Fellowship:

    • Medical Staff Fellow in Hematopathology, National Cancer Institute, National Institutes of Health, 1981-1984
  • Certifications:

    • Anatomic & Clinical Pathology, American Board of Pathology, 1981

Publications

  • "Combined copy number and mutation analysis identifies oncogenic pathways associated with transformation of follicular lymphoma." Leukemia In: , 08.07.2016.
  • "Targeted next-generation sequencing in myelodysplastic syndrome and chronic myelomonocytic leukemia aids diagnosis in challenging cases and identifies frequent spliceosome mutations in transformed acute myeloid leukemia." American Journal of Clinical Pathology  In: , Vol. 145, No. 4, 01.04.2016, p. 497-506.
  • "Identification of primary mediastinal large B-cell lymphoma at nonmediastinal sites by gene expression profiling." American Journal of Surgical Pathology In: , Vol. 39, No. 10, 01.10.2015, p. 1322-1330.
  • "Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status." Leukemia and Lymphoma In: , 27.08.2015.
  • "Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia." Oncogene In: , Vol. 34, No. 23, 04.06.2015, p. 2991-2999.
  • "Global microRNA expression profiling uncovers molecular markers for classification and prognosis in aggressive B-cell lymphoma." Blood In: , Vol. 125, No. 7, 12.02.2015, p. 1137-1145.
  • "Loss of signalling via G α 13 in germinal centre B-cell-derived lymphoma." Nature In: , Vol. 516, No. 7530, 11.12.2014, p. 254-258.
  • "BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma." Human Pathology In: , Vol. 45, No. 10, 01.10.2014, p. 2144-2153.
  • "Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma." Blood In: , Vol. 123, No. 19, 08.05.2014, p. 2915-2923.
  • "Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma." Blood  In: , Vol. 123, No. 11, 13.03.2014, p. 1681-1690.
  • "Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue." Blood In: , Vol. 123, No. 8, 20.02.2014, p. 1214-1217.
  • "Essential role of the linear ubiquitin chain assembly complex in lymphoma revealed by rare germline polymorphisms." Cancer Discovery In: , Vol. 4, No. 4, 2014, p. 480-493.
  • "Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP." Journal of Clinical Oncology  In: , Vol. 31, No. 36, 30.12.2013, p. 4520-4528.
  • "Genome-wide methylation analyses identify a subset of mantle cell lymphoma with a high number of methylated CpGs and aggressive clinicopathological features." International Journal of Cancer  In: , Vol. 133, No. 12, 15.12.2013, p. 2852-2863.
  • "A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine- tositumomab." Clinical Cancer Research In: , Vol. 19, No. 23, 01.12.2013, p. 6624-6632.
  • "EZH2 mutations are frequent and represent an early event in follicular lymphoma." Blood  In: , Vol. 122, No. 18, 31.10.2013, p. 3165-3168.
  • "Colorimetric in situ hybridization identifies MYC gene signal clusters correlating with increased copy number, mRNA, and protein in diffuse large b-cell lymphoma." American Journal of Clinical Pathology  In: , Vol. 139, No. 2, 02.2013, p. 242-254.
  • "Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus 131iodine-tositumomab for previously untreated follicular non-hodgkin lymphoma : SWOG S0016." Journal of Clinical Oncology In: , Vol. 31, No. 3, 20.01.2013, p. 314-320.
  • "Diffuse large B-cell lymphoma in adults aged 75 years and older : A single institution analysis of cause-specific survival and prognostic factors." Therapeutic Advances in Hematology  In: , Vol. 4, No. 6, 2013, p. 349-353.
  • "Multiplex high-throughput gene mutation analysis in acute myeloid leukemia." Human Pathology  In: , Vol. 43, No. 12, 12.2012, p. 2167-2176.
  • "Reply to "Fc gamma receptor 3a genotype in follicular lymphoma : The end of the story?" Haematologica. 2012;97(11): e45." Haematologica In: , Vol. 97, No. 11, 01.11.2012.
  • "Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics." Nature In: , Vol. 490, No. 7418, 04.10.2012, p. 116-120.
  • "Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone." Journal of Clinical Oncology In: , Vol. 30, No. 28, 01.10.2012, p. 3452-3459.
  • "IL-10 -1082 SNP and IL-10 in primary CNS and vitreoretinal lymphomas." Graefe's Archive for Clinical and Experimental Ophthalmology  In: , Vol. 250, No. 10, 10.2012, p. 1541-1548.
  • "A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma." Blood In: , Vol. 120, No. 11, 13.09.2012, p. 2290-2296.
  • "Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone." Haematologica In: , Vol. 97, No. 6, 01.06.2012, p. 937-942.
  • "Genome-wide miRNA profiling of mantle cell lymphoma reveals a distinct subgroup with poor prognosis." Blood In: , Vol. 119, No. 21, 24.05.2012, p. 4939-4948.
  • "RAS mutations in therapy-related acute myeloid leukemia after successful treatment of acute promyelocytic leukemia." Leukemia and Lymphoma  In: , Vol. 53, No. 5, 05.2012, p. 999-1002.
  • "BCL2 predicts survival in germinal center B-cell-like diffuse large B-cell lymphoma treated with CHOP-like therapy and rituximab." Clinical Cancer Research In: , Vol. 17, No. 24, 15.12.2011, p. 7785-7795.
  • "MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype." Blood  In: , Vol. 118, No. 20, 17.11.2011, p. 5550-5558.

Additional information

Edit profile